Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin for neurorecovery after moderate-severe traumatic brain injury
2024-515591-12-00Phase 4Unknown
- Sponsor
- Foundation for the Study of Nanoneurosciences and Neuroregeneration
- Start
- Aug 2024
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in traumatic brain injury (TBI) comparing Cerebrolysin with Placebo (2 arms). Primary endpoint: Glasgow Outcome Scale Extended outcome at 90 days after baseline. Status: unknown.
02
Drugs
cerebrolysin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2024-515591-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515591-12-00.